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There are reports in the literature showing one of the essential amino acids (AAs), leucine, playing a role in enhancing cognition and memory in animal and man, partially via the mammalian target of rapamycin (mTOR) signaling pathway regulating neuronal protein synthesis and plasticity. This pathway is a potential target for modulation with leucine (or other therapeutic agents), to maintain/enhance normal functioning under stress conditions. Such an effect has potential for optimizing warfighter cognitive performance under high demand conditions. The kinetic behavior of leucine is, however, not well characterized. Most published studies involve uptake of leucine-enhanced drinking water or diet, and concentrations of leucine in tissues are typically measured at only one time point at the study's end (Tews and Harper 1991) . To fill these data gaps and to develop a physiologically-based pharmacokinetic (PBPK) leucine model, an iv leucine study was performed in Long-Evans rats, collecting both time-course and dose-response blood and tissue data. Such a PBPK model, once validated, will allow extrapolation of leucine dosing and intake across dosing regimens (drinking water, diet) and across species to predict potential brain concentration changes in man. Brain concentrations in both animals and man can then be linked with potential impacts on the mTOR signaling pathway, and on observed cognitive changes. Preliminary results revealed that leucine is eliminated from the blood very quickly after iv dosing (5mg/kg), and leucine levels in the brain were higher than blood, indicating active transport of leucine across the blood-brain-barrier (BBB). At 5 min post dosing, only 7% of injected leucine was detected still in blood, and at 6 hr post doing it was down to base line levels. Similarly, of the 17 other AAs measured in brain, about 2/3 were increased, even at very early times (<2 min) after iv leucine injection. Most of those that either remained unchanged or were increased in brain are known to be transported across the BBB by the L1 large neutral AA transporter (Smith, 2000; Wade, 1981) . Thus, since this system is normally close to saturation, and since leucine has a high affinity for this transporter, one may speculate that the spike in leucine levels due to the iv injection tends to cause an increased brain influx of ALL AA's, but that competition for the L1 transporter mitigates this effect somewhat for many of the AAs that primarily make use of this system to enter the brain. There are reports in the literature showing one of the essential amino acids (AAs), leucine, playing a role in enhancing cognition and memory in animal and man, partially via the mammalian target of rapamycin (mTOR) signaling pathway regulating neuronal protein synthesis and plasticity (Hoeffer and Klann, 2009; Sarbassoy et al 2005; Tokunaga et al 2004) . This pathway is a potential target for modulation with leucine (or other therapeutic agents), to maintain (or even enhance) normal functioning under stress conditions. Such an effect has potential for optimizing warfighter cognitive performance under high demand conditions. The kinetic behavior of leucine is, however, not well characterized. Most published studies involve uptake of leucine-enhanced drinking water or diet, and concentrations of leucine in tissues are typically measured at only one time point at the study's end (Tews and Harper 1991) . To fill these data gaps and to develop a physiologically-based pharmacokinetic (PBPK) leucine model, an iv leucine study was performed in Long-Evans rats, collecting both time-course and doseresponse blood and tissue data. Such a PBPK model, once validated, will allow extrapolation of leucine dosing and intake across dosing regimens (drinking water, diet) and across species to predict potential brain concentration changes in man. Brain concentrations in both animals and man can then be linked with potential impacts on the mTOR signaling pathway, and on observed cognitive changes. Preliminary results revealed that leucine is eliminated from the blood very quickly after iv dosing (5mg/kg), and leucine levels in the brain were higher than blood, indicating active transport of leucine across the blood-brain-barrier (BBB). At 5 min post dosing, only 7% of injected leucine was detected still in blood, and at 6 hr post doing it was down to base line levels. Similarly, of the 17 other AAs measured in brain, about 2/3 were increased, even at very early times (<2 min) after iv leucine injection. Most of those that either remained unchanged or were increased in brain are known to be transported across the BBB by the L1 large neutral AA transporter (Smith, 2000; Wade, 1981) . Thus, since this system is normally close to saturation, and since leucine has a high affinity for this transporter, one may speculate that the spike in leucine levels due to the iv injection tends to cause an increased brain influx of ALL AA's, but that competition for the L1 transporter mitigates this effect somewhat for many of the AAs that primarily make use of this system to enter the brain.
• Leucine, an essential amino acid, has been linked with cognitive enhancement in both experimental animals and humans
• Leucine is involved in the regulation of the mTOR (mammalian target of rapamycin) pathway
• The mTOR pathway regulates protein synthesis in cells, including neurons
• Neuronal protein synthesis is associated with synaptic plasticity and memory consolidation
• There is a need to link in vivo leucine exposures, via drinking water, diet, and other routes, with brain leucine levels, in order to develop dosing regimens with the potential for cognitive enhancement in humans (dose-response).
• Development of mechanism-based mathematical models, including a physiologicallybased pharmacokinetic (PBPK) model for leucine will help provide such a (quantitative) link
• In order to develop such a model for leucine, we performed an iv study in rats, in which leucine was measured in blood, brain and other tissues at various times after injection.
• Since leucine is part of a dynamic system involving other amino acids, which interact with leucine in various ways (such as competition for transport across the blood-brain barrier -see Table 1 ), other amino acid blood and brain levels were also measured. • Dosing levels: 5 and 12.9 mg/kg leucine in physiological saline (Fig 1a) . Leucine was eliminated very fast from the circulating blood. Control values were subtracted. Table 2 . Percentage increase or decrease of other amino acids: following iv leucine injection. Rats were dosed with two doses (5 & 12.9 mg/kg) of leucine, and blood and brain were harvested at different time points (0-6h). Effects of leucine on the other amino acids were compared. Percentage of increase or decrease were reported as the average values of 6 time points.
